Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin

Azuma,Takeshi; Nagase,Yasushi; Oshi,Masaya

doi:10.3892/mco.2015.582

Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin

Authors:
- Takeshi Azuma
- Yasushi Nagase
- Masaya Oshi
View Affiliations

Affiliations: Department of Urology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo 183-0042, Japan
Published online on: June 15, 2015 https://doi.org/10.3892/mco.2015.582
Pages: 1113-1116

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was conducted to evaluate the utility of pyuria as a predictive marker of bacillus Calmette-Guérin (BCG) treatment for non-muscle-invasive bladder cancer (NMIBC). A cohort of 243 NMIBC patients treated with BCG through intravesical instillation between 1994 and 2007 at the Tokyo Metropolitan Tama Medical Center were enrolled in this retrospective study. Pyuria was defined as urine containing ≥10 white blood cells per high‑power field. A total of 30 of the patients with pyuria (30̸37, 81%) and 87 patients of those without pyuria (87̸206, 42%) exhibited recurrence following BCG treatment. The 3-year recurrence‑free survival rate of patients with and without pyuria following BCG treatment was 20 and 62%, respectively. The multivariate Cox proportional hazards regression model indicated that pyuria was an independent predictor of disease recurrence following BCG treatment. Patients with inflammatory NMIBC exhibited resistance to therapy with intravesical instillation of BCG.

View Figures

View References

1	Brake M, Loertzer H, Horsch R and Keller H: Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guérin. J Urol. 163:1697–1701. 2000. View Article : Google Scholar : PubMed/NCBI
2	Brake M, Loertzer H, Horsch R and Keller H: Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer. Urology. 55:673–678. 2000. View Article : Google Scholar : PubMed/NCBI
3	Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A and Debruyne FM: Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol. 147:596–600. 1992.PubMed/NCBI
4	Lima L, Dinis-Ribeiro M, Longatto-Filho A and Santos L: Predictive biomarkers of bacillus Calmette-Guérin immunotherapy response in bladder cancer: Where are we now? Adv Urol. 2012:2326092012. View Article : Google Scholar : PubMed/NCBI
5	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
6	Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene. 27:5904–5912. 2008. View Article : Google Scholar : PubMed/NCBI
7	Azuma T, Nagase Y and Oshi M: Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 11:331–336. 2013. View Article : Google Scholar : PubMed/NCBI
8	Echols RM, Tosiello RL, Haverstock DC and Tice AD: Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis. 29:113–119. 1999. View Article : Google Scholar : PubMed/NCBI
9	Mostofi FK, Sobin LH and Tosoni I: Histological Typing of Urinary Bladder TumoursInternational Histological Classification of Tumours, No 19. World Health Organisation; Geneva: 1973
10	Nieder AM, Brausi M, Lamm D, O'Donnell M, Tomita K, Woo H and Jewett MA: Management of stage T1 tumors of the bladder: International Consensus Panel. Urology. 66:(Suppl 1). 108–125. 2005. View Article : Google Scholar : PubMed/NCBI
11	Hagemann T, Balkwill F and Lawrence T: Inflammation and cancer: A double-edged sword. Cancer Cell. 12:300–301. 2007. View Article : Google Scholar : PubMed/NCBI
12	Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F and Vicente-Rodríguez J: Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 164:680–684. 2000. View Article : Google Scholar : PubMed/NCBI
13	Zuiverloon TC, Nieuweboer AJ, Vékony H, Kirkels WJ, Bangma CH and Zwarthoff EC: Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: A systematic review. Eur Urol. 61:128–145. 2012. View Article : Google Scholar : PubMed/NCBI
14	Donskov F and von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 24:1997–2005. 2006. View Article : Google Scholar : PubMed/NCBI
15	Ilie M, Hofman V, Ortholan C, Bonnetaud C, Coëlle C, Mouroux J and Hofman P: Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. 118:1726–1737. 2012. View Article : Google Scholar : PubMed/NCBI
16	Hinotsu S, Akaza H, Isaka S, et al: BCG Tokyo 172 Strain Study Group: Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: A smoothed hazard analysis in a randomized prospective study. Urology. 67:545–549. 2006. View Article : Google Scholar : PubMed/NCBI
17	Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol. 163:1124–1129. 2000. View Article : Google Scholar : PubMed/NCBI